Hypertension – Alnylam Pharmaceuticals ALN-AGT01-008

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.

Inclusion Criteria:

• Is 18 years or older for patients with established cardiovascular disease (CVD)
• Is 55 years or older for patients with high risk for CVD
• Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD
• Has treated hypertension on stable therapy with at least 2 standards of care antihypertensive medications, one of which must be a thiazide, thiazide-like, or loop diuretic
• Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.